PT1339398E - Tratamento de flutuações motoras - Google Patents

Tratamento de flutuações motoras Download PDF

Info

Publication number
PT1339398E
PT1339398E PT01976536T PT01976536T PT1339398E PT 1339398 E PT1339398 E PT 1339398E PT 01976536 T PT01976536 T PT 01976536T PT 01976536 T PT01976536 T PT 01976536T PT 1339398 E PT1339398 E PT 1339398E
Authority
PT
Portugal
Prior art keywords
hydroxytryptamine
receptor activity
treatment
motor fluctuations
activity enhancing
Prior art date
Application number
PT01976536T
Other languages
English (en)
Inventor
Jonathan Brotchie
Michael Hill
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9902589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1339398(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Publication of PT1339398E publication Critical patent/PT1339398E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing Of Meat And Fish (AREA)
  • Paper (AREA)
  • Threshing Machine Elements (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT01976536T 2000-11-03 2001-10-29 Tratamento de flutuações motoras PT1339398E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0027020.7A GB0027020D0 (en) 2000-11-03 2000-11-03 Treatment of movement disorders

Publications (1)

Publication Number Publication Date
PT1339398E true PT1339398E (pt) 2008-11-03

Family

ID=9902589

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01976536T PT1339398E (pt) 2000-11-03 2001-10-29 Tratamento de flutuações motoras

Country Status (13)

Country Link
US (2) US20040067956A1 (pt)
EP (1) EP1339398B1 (pt)
JP (2) JP5189240B2 (pt)
AT (1) ATE406880T1 (pt)
AU (2) AU2001295804B2 (pt)
CA (1) CA2431641A1 (pt)
CY (1) CY1108628T1 (pt)
DE (1) DE60135675D1 (pt)
DK (1) DK1339398T3 (pt)
ES (1) ES2311549T3 (pt)
GB (1) GB0027020D0 (pt)
PT (1) PT1339398E (pt)
WO (1) WO2002036107A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
PT2908805T (pt) * 2012-10-22 2021-09-10 Civitas Therapeutics Inc Formulações de levodopa para alívio rápido da doença de parkinson

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013766A1 (en) * 1992-01-07 1993-07-22 Merrell Dow Pharmaceuticals Inc. Treatment of involuntary movements with 5ht1a receptor agonists
EP0697894A4 (en) * 1993-03-31 1996-05-01 Univ Pennsylvania DOPAMINE D-3 AND SEROTONIN (5-HT 1A) RECEPTOR LIGANDS AND IMAGING AGENTS
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
EA015073B1 (ru) 2006-06-16 2011-04-29 Солвей Фармасьютикалс Б.В. Комбинированные препараты, содержащие slv308 и l-dopa
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
RU2010107036A (ru) 2007-11-30 2011-08-27 Дайити Санке Компани, Лимитед (Jp) Лекарственное средство для облегчения двигательных нарушений или психиатрических симптомов при болезни паркинсона

Also Published As

Publication number Publication date
EP1339398B1 (en) 2008-09-03
US20110178178A1 (en) 2011-07-21
AU2001295804B2 (en) 2007-01-04
DE60135675D1 (de) 2008-10-16
CA2431641A1 (en) 2002-05-10
JP2004512360A (ja) 2004-04-22
US9668995B2 (en) 2017-06-06
EP1339398A2 (en) 2003-09-03
US20040067956A1 (en) 2004-04-08
JP5189240B2 (ja) 2013-04-24
ATE406880T1 (de) 2008-09-15
AU9580401A (en) 2002-05-15
DK1339398T3 (da) 2009-01-26
WO2002036107A2 (en) 2002-05-10
GB0027020D0 (en) 2000-12-20
WO2002036107A3 (en) 2003-01-16
ES2311549T3 (es) 2009-02-16
CY1108628T1 (el) 2014-04-09
JP2010241827A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
HK1049284A1 (en) Benzimidazole compounds having nociceptin receptoraffinity
BG108495A (en) 5-ht receptor ligands and uses thereof
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE60112974D1 (en) Carbolinderivate
CR6393A (es) Moduladores de ccr5
DE60216233D1 (en) Carbolinderivate
HK1069171A1 (en) Substituted 6H-dibenzioÄc,hÜchromenes as estrogenic agents.
HK1068274A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
MXPA02006167A (es) Promocion de la angiogenesis con survivina.
HK1061340A1 (en) Activity control during dieting
CY1108628T1 (el) Θεραπεια των κινητικων διακυμανσεων με ενωσεις ενισχυσης της δραστηριοτητας του υποδοχεα 5-υδροξυτρυπταμινη 1α
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
GB9924941D0 (en) Treatment of dyskinesia
UA87813C2 (ru) Система контролируемого высвобождения темозоломида
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
EP1406605A4 (en) 2-HETEROCYCLIC 1,2-ETHANEDIOL CARBAMATES
WO2002007766A8 (en) Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia
ZA200204455B (en) Use of dopamine-D3 receptor agonists for the therapy of salt-dependent hypertension.
WO2003070177A3 (en) Use of melatonin analogues for induction of general anesthesia
UA32278A (uk) S, o-етилен (о,о-диетилтіофосфорил)-диетилтіофосфат, володіючий інсектицидною активністю
IT1307108B1 (it) Macchina palissonatrice per pelli.